Related Experiment Videos
Atrial fibrillation in the elderly: physicians' attitudes to anticoagulation
1Clatterbridge Hospital, Wirral, Merseyside.
The British Journal of Clinical Practice
|May 1, 1995
Summary
Warfarin and aspirin use for stroke prevention in atrial fibrillation (AF) varies among specialists. Cardiologists favor warfarin more in certain conditions and for younger patients compared to geriatricians.
Area of Science:
- Cardiology
- Geriatrics
- Neurology
Background:
- Atrial fibrillation (AF) increases stroke risk, necessitating preventative strategies.
- The optimal antithrombotic therapy (warfarin vs. aspirin) for primary stroke prevention in AF remains debated, particularly in elderly populations.
- Current clinical practice patterns for antithrombotic prescribing in AF are not fully elucidated.
Purpose of the Study:
- To investigate and compare the prescribing practices of geriatricians and cardiologists regarding warfarin and aspirin for primary stroke prevention in patients with atrial fibrillation (AF).
- To identify factors influencing the choice between warfarin and aspirin based on specific cardiac conditions and patient demographics.
Main Methods:
- A questionnaire survey was distributed to 300 geriatricians and 300 cardiologists to assess their current practices.
- Response rates were 47% for geriatricians and 51% for cardiologists.
- Data analysis compared prescribing preferences between the two specialist groups across different AF etiologies.
Main Results:
- Warfarin was the preferred agent for AF with mitral stenosis by both groups (86% G vs. 89% C).
- Cardiologists were significantly more likely to prescribe warfarin for AF with dilated cardiomyopathy (52% G vs. 86% C, P < 0.01).
- Aspirin was favored over warfarin for lone AF and AF with aortic valve disease by both groups, with cardiologists showing a greater preference for warfarin in lone AF (10% G vs. 26% C, P < 0.01). Cardiologists were also less hesitant to use warfarin in younger patients.
Conclusions:
- Prescribing patterns for antithrombotic therapy in atrial fibrillation differ between geriatricians and cardiologists.
- Cardiologists demonstrate a broader acceptance of warfarin, particularly in specific cardiomyopathies and for younger individuals.
- Further research is warranted to optimize stroke prevention strategies in AF based on specialist-driven evidence.